Pub Date : 2017-11-01Epub Date: 2017-11-20DOI: 10.2217/ijh-2017-0009
Fotini Debonera, Sunita Nasta, Maria Martinez-Lage, Stephen J Schuster, Donald E Tsai
There is no consensus on the optimal therapy for primary CNS lymphoma. Conventional treatment modalities include chemotherapy and radiation therapy, which carry significant risks of morbidity and mortality. In systemic lymphomas, there are situations where non-Hodgkin lymphomas have resolved spontaneously. We now report the case of a nonimmunocompromised patient with primary CNS lymphoma who underwent a spontaneous remission with a durable response. This case suggests that not all patients with primary CNS lymphomas require aggressive treatment with chemotherapy and radiation therapy.
{"title":"Primary diffuse large B-cell lymphoma of the CNS: a rare case of spontaneous remission.","authors":"Fotini Debonera, Sunita Nasta, Maria Martinez-Lage, Stephen J Schuster, Donald E Tsai","doi":"10.2217/ijh-2017-0009","DOIUrl":"https://doi.org/10.2217/ijh-2017-0009","url":null,"abstract":"<p><p>There is no consensus on the optimal therapy for primary CNS lymphoma. Conventional treatment modalities include chemotherapy and radiation therapy, which carry significant risks of morbidity and mortality. In systemic lymphomas, there are situations where non-Hodgkin lymphomas have resolved spontaneously. We now report the case of a nonimmunocompromised patient with primary CNS lymphoma who underwent a spontaneous remission with a durable response. This case suggests that not all patients with primary CNS lymphomas require aggressive treatment with chemotherapy and radiation therapy.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36609875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-11-01Epub Date: 2017-11-20DOI: 10.2217/ijh-2017-0010
Claudio Agostinelli
“ The results indicate that response-adapted therapy based on PET-2 results guarantees a PFS, in PET-2 positive patients and in the overall cohort, higher than PFS of historical controls treated with ABVD. ”
{"title":"How can we better predict treatment outcomes in classical Hodgkin's lymphoma?","authors":"Claudio Agostinelli","doi":"10.2217/ijh-2017-0010","DOIUrl":"https://doi.org/10.2217/ijh-2017-0010","url":null,"abstract":"“ The results indicate that response-adapted therapy based on PET-2 results guarantees a PFS, in PET-2 positive patients and in the overall cohort, higher than PFS of historical controls treated with ABVD. ”","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568756","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-11-01Epub Date: 2017-11-20DOI: 10.2217/ijh-2017-0018
Christopher J Ott
“ there is intriguing experimental evidence to suggest targeting gene regulatory factors with pharmaceutical agents could be an effective therapeutic strategy for B-ALL. ” Modern chemotherapy regimens have had a profound impact on the prognosis of individuals diagnosed with B-cell acute lymphoblastic leukemia (B-ALL), especially children [1] . However these treatments achieve substantially poorer survival rates in adults, and are associated with significant short- and long-term toxicities. An advanced understanding of the genetic complexity that characterizes B-ALL allows for more precise patient stratification, and reveals disease subtypes that are at a high-risk for treatment relapse [2] . This genetic profiling has also revealed opportunities for the development of targeted therapies. For example, recurrent BCR–ABL1 translocations define a unique subtype of ALL found in 2–4% of pediatric and at least 25% of adult cases. The activity of this oncogene can be effectively inhibited with the tyrosine kinase inhibitor imatinib, with promising clinical results [3] . Intriguingly, many ALL oncogenes include gene fusions and translocations of transcription regulators and other chromatin associated factors (e.g., ETV6–RUNX1 , TCF3–PBX1 , MYC or MLL rearrangements), revealing the disease to be primarily one of disrupted gene expression control. The mechanistic aspects of these oncogenes are incompletely understood, yet remain an active area of research. These factors can unfortunately also often be viewed as intractable for therapeutics development. Yet much recent progress has been made in targeting gene regulatory complexes with small molecule pharmaceutical agents [4] . Additionally, promising preclinical and early clinical data in B-ALL
{"title":"Opportunities for targeting gene regulatory factors in B-cell acute lymphoblastic leukemia.","authors":"Christopher J Ott","doi":"10.2217/ijh-2017-0018","DOIUrl":"https://doi.org/10.2217/ijh-2017-0018","url":null,"abstract":"“ there is intriguing experimental evidence to suggest targeting gene regulatory factors with pharmaceutical agents could be an effective therapeutic strategy for B-ALL. ” Modern chemotherapy regimens have had a profound impact on the prognosis of individuals diagnosed with B-cell acute lymphoblastic leukemia (B-ALL), especially children [1] . However these treatments achieve substantially poorer survival rates in adults, and are associated with significant short- and long-term toxicities. An advanced understanding of the genetic complexity that characterizes B-ALL allows for more precise patient stratification, and reveals disease subtypes that are at a high-risk for treatment relapse [2] . This genetic profiling has also revealed opportunities for the development of targeted therapies. For example, recurrent BCR–ABL1 translocations define a unique subtype of ALL found in 2–4% of pediatric and at least 25% of adult cases. The activity of this oncogene can be effectively inhibited with the tyrosine kinase inhibitor imatinib, with promising clinical results [3] . Intriguingly, many ALL oncogenes include gene fusions and translocations of transcription regulators and other chromatin associated factors (e.g., ETV6–RUNX1 , TCF3–PBX1 , MYC or MLL rearrangements), revealing the disease to be primarily one of disrupted gene expression control. The mechanistic aspects of these oncogenes are incompletely understood, yet remain an active area of research. These factors can unfortunately also often be viewed as intractable for therapeutics development. Yet much recent progress has been made in targeting gene regulatory complexes with small molecule pharmaceutical agents [4] . Additionally, promising preclinical and early clinical data in B-ALL","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568754","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-06-01Epub Date: 2017-11-17DOI: 10.2217/ijh-2017-0007
Stefano Molica
“ the advent of targeted therapy in CLL requires the urgent introduction of revised clinical guidelines based not only on results of clinical trials but also including data from clinical practice and the assessment of drug-related toxicity according patients’ reported outcomes ”
{"title":"Chronic lymphocytic leukemia: <i>\"The times they are a-changin\"</i>.","authors":"Stefano Molica","doi":"10.2217/ijh-2017-0007","DOIUrl":"https://doi.org/10.2217/ijh-2017-0007","url":null,"abstract":"“ the advent of targeted therapy in CLL requires the urgent introduction of revised clinical guidelines based not only on results of clinical trials but also including data from clinical practice and the assessment of drug-related toxicity according patients’ reported outcomes ”","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0007","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-06-01Epub Date: 2017-06-30DOI: 10.2217/ijh-2017-0006
Pier Paolo Piccaluga
{"title":"Updated classification and novel treatment prospective for nodal peripheral T-cell lymphomas.","authors":"Pier Paolo Piccaluga","doi":"10.2217/ijh-2017-0006","DOIUrl":"https://doi.org/10.2217/ijh-2017-0006","url":null,"abstract":"","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-06-01Epub Date: 2017-06-30DOI: 10.2217/ijh-2017-0003
Maryam Sarraf Yazdy, Chaitra Ujjani
Although typically indolent in nature, follicular lymphoma remains an ongoing challenge for practicing oncologists. While response rates >90% can be achieved with rituximab-based chemoimmunotherapy in advanced stage patients, the complete remission rates are substantially lower and patients inevitably relapse. The inability to achieve a complete remission and an early progression of disease have recently been determined to be indicative of poorer long-term outcomes. A greater understanding of the pathogenesis of follicular lymphoma has enabled the development of targeted therapies, which may improve standard treatment approaches. Examples include lenalidomide and obinutuzumab, which are currently in front-line Phase III investigation. Other therapies of interest include small molecule inhibitors, immune checkpoint inhibitors and chimeric antigen receptor T cells.
滤泡性淋巴瘤是一种典型的懒散性淋巴瘤,但对于肿瘤医生来说,它仍然是一项持续的挑战。虽然晚期患者使用利妥昔单抗化疗免疫疗法可获得大于90%的应答率,但完全缓解率却低得多,而且患者不可避免地会复发。无法实现完全缓解和疾病早期进展最近被确定为长期疗效较差的指标。随着人们对滤泡性淋巴瘤发病机理的进一步了解,靶向疗法得以开发,这可能会改善标准治疗方法。例如来那度胺和奥比奴珠单抗,这两种药物目前正处于前线III期研究阶段。其他值得关注的疗法包括小分子抑制剂、免疫检查点抑制剂和嵌合抗原受体 T 细胞。
{"title":"Current challenges in the management of follicular lymphoma.","authors":"Maryam Sarraf Yazdy, Chaitra Ujjani","doi":"10.2217/ijh-2017-0003","DOIUrl":"10.2217/ijh-2017-0003","url":null,"abstract":"<p><p>Although typically indolent in nature, follicular lymphoma remains an ongoing challenge for practicing oncologists. While response rates >90% can be achieved with rituximab-based chemoimmunotherapy in advanced stage patients, the complete remission rates are substantially lower and patients inevitably relapse. The inability to achieve a complete remission and an early progression of disease have recently been determined to be indicative of poorer long-term outcomes. A greater understanding of the pathogenesis of follicular lymphoma has enabled the development of targeted therapies, which may improve standard treatment approaches. Examples include lenalidomide and obinutuzumab, which are currently in front-line Phase III investigation. Other therapies of interest include small molecule inhibitors, immune checkpoint inhibitors and chimeric antigen receptor T cells.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6171972/pdf/ijh-06-13.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-06-01Epub Date: 2017-06-30DOI: 10.2217/ijh-2017-0008
Amit Sud
Amit Sud speaks to Sebastian Dennis-Beron, Commissioning Editor: Amit Sud is a clinical research fellow in Hematology at the Institute of Cancer Research, UK. He undertook his undergraduate medical training at the University of Manchester, gaining an honors degree. He completed his Masters in Medical Research at Manchester University, gaining a distinction. He continued his medical training in Manchester and London and started his specialization in Hematology in South West London. He was successful in obtaining a Cancer Research UK funded clinical research fellowship in Hematology under the supervision of Professor Richard Houlston at the Institute of Cancer Research. His current research focus is that of genetic susceptibility to Hodgkin lymphoma. He is a trainee member of the NCRI Lymphoma Clinical Studies Group.
Amit Sud与特约编辑Sebastian Dennis-Beron对话:Amit Sud是英国癌症研究所血液学临床研究员。他在曼彻斯特大学接受了本科医学培训,并获得了荣誉学位。他在曼彻斯特大学完成了医学研究硕士学位,并获得了优异的成绩。他在曼彻斯特和伦敦继续他的医学培训,并在伦敦西南部开始他的血液学专业。在癌症研究所Richard Houlston教授的指导下,他成功地获得了英国癌症研究中心资助的血液学临床研究奖学金。他目前的研究重点是霍奇金淋巴瘤的遗传易感性。他是NCRI淋巴瘤临床研究小组的实习成员。
{"title":"Survivors at risk: Hodgkin lymphoma survivors at high risk of second cancers.","authors":"Amit Sud","doi":"10.2217/ijh-2017-0008","DOIUrl":"https://doi.org/10.2217/ijh-2017-0008","url":null,"abstract":"<p><p><b>Amit Sud speaks to Sebastian Dennis-Beron, Commissioning Editor:</b> Amit Sud is a clinical research fellow in Hematology at the Institute of Cancer Research, UK. He undertook his undergraduate medical training at the University of Manchester, gaining an honors degree. He completed his Masters in Medical Research at Manchester University, gaining a distinction. He continued his medical training in Manchester and London and started his specialization in Hematology in South West London. He was successful in obtaining a Cancer Research UK funded clinical research fellowship in Hematology under the supervision of Professor Richard Houlston at the Institute of Cancer Research. His current research focus is that of genetic susceptibility to Hodgkin lymphoma. He is a trainee member of the NCRI Lymphoma Clinical Studies Group.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0008","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36205089","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-06-01Epub Date: 2017-06-30DOI: 10.2217/ijh-2017-0014
Susan Paskar
Susan Paskar speaks to Sebastian Dennis-Beron, Commissioning Editor: Susan qualified in 1997 as a registered nurse and has 20 years of experience, in a range of specialties including hematology, medical and surgical oncology, general surgery, bariatric, breast, endocrine, head & neck, liver, urology and bone marrow/stem cell transplant. Working in both the UK and the USA, in regional transplant centers since 2002, she is considered expert in care of the bone marrow transplant patient from point of referral to long term follow-up care and palliation. She has been responsible for development and implementation of a Nurse-led late-effects post-bone marrow transplant service at the Freeman Hospital in Newcastle upon Tyne, as their Anthony Nolan Nurse Specialist.
{"title":"The bone marrow transplant clinical nurse specialist in hemato-oncology: an interview with Anthony Nolan Nurse Specialist Susan Paskar.","authors":"Susan Paskar","doi":"10.2217/ijh-2017-0014","DOIUrl":"https://doi.org/10.2217/ijh-2017-0014","url":null,"abstract":"<p><p><b>Susan Paskar speaks to Sebastian Dennis-Beron, Commissioning Editor:</b> Susan qualified in 1997 as a registered nurse and has 20 years of experience, in a range of specialties including hematology, medical and surgical oncology, general surgery, bariatric, breast, endocrine, head & neck, liver, urology and bone marrow/stem cell transplant. Working in both the UK and the USA, in regional transplant centers since 2002, she is considered expert in care of the bone marrow transplant patient from point of referral to long term follow-up care and palliation. She has been responsible for development and implementation of a Nurse-led late-effects post-bone marrow transplant service at the Freeman Hospital in Newcastle upon Tyne, as their Anthony Nolan Nurse Specialist.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0014","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-06-01Epub Date: 2017-07-18DOI: 10.2217/ijh-2017-0011
Jason A Powell, Craig T Wallington-Beddoe, Stuart M Pitson
Acute myeloid leukemia (AML) is an aggressive heterogeneous group of malignancies resulting from various oncogenic genetic lesions that presents as an accumulation of immature myeloid cells in the bone marrow and peripheral blood. Standard induction chemotherapeutics have remained the front line therapy for AML for over 30 years, and despite being often highly effective at achieving initial disease remission, these responses are often short-lived resulting in relapse and death. Indeed, the overall survival in young adults ( < 60 years) is < 30% [1] . Unlike the ever-increasing repertoire of targeted therapies for lymphoproliferative disorders, currently all- trans-retinoic-acid represents the only targeted therapy in routine clinical use for the treatment of one subclass of AML, acute promyelocytic leukemia, with this approach yielding a more favorable prognosis in this AML subtype than presently achievable in any other form of AML. No targeted therapies are in routine clinical use for the remaining subtypes of AML, which constitute about 90% of all AML patients, and thus, there is an enormous unmet need to develop such targeted therapies.
{"title":"Targeting sphingosine kinase 1 in acute myeloid leukemia: translation to clinic.","authors":"Jason A Powell, Craig T Wallington-Beddoe, Stuart M Pitson","doi":"10.2217/ijh-2017-0011","DOIUrl":"https://doi.org/10.2217/ijh-2017-0011","url":null,"abstract":"Acute myeloid leukemia (AML) is an aggressive heterogeneous group of malignancies resulting from various oncogenic genetic lesions that presents as an accumulation of immature myeloid cells in the bone marrow and peripheral blood. Standard induction chemotherapeutics have remained the front line therapy for AML for over 30 years, and despite being often highly effective at achieving initial disease remission, these responses are often short-lived resulting in relapse and death. Indeed, the overall survival in young adults ( < 60 years) is < 30% [1] . Unlike the ever-increasing repertoire of targeted therapies for lymphoproliferative disorders, currently all- trans-retinoic-acid represents the only targeted therapy in routine clinical use for the treatment of one subclass of AML, acute promyelocytic leukemia, with this approach yielding a more favorable prognosis in this AML subtype than presently achievable in any other form of AML. No targeted therapies are in routine clinical use for the remaining subtypes of AML, which constitute about 90% of all AML patients, and thus, there is an enormous unmet need to develop such targeted therapies.","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2017-06-01Epub Date: 2017-11-17DOI: 10.2217/ijh-2017-0002
Alicja M Gruszka, Debora Valli, Myriam Alcalay
Although the treatment modalities for acute myeloid leukemia (AML) have not changed much over the past 40 years, distinct progress has been made in deciphering the basic biology underlying the pathogenesis of this group of hematological disorders. Studies show that AML development is a multicause, multistep and multipathway process. Accordingly, AMLs constitute a heterogeneous group of diseases. The thorough understanding of the molecular basis of AML is paving the way for better therapeutic approaches. Multiple novel drugs are being introduced and new, more efficient and less toxic formulations of conventional therapeutics are becoming available. Here, we review the recent advances in the comprehension of the molecular processes that lead to the onset of AML and its translation into clinical practice.
{"title":"Understanding the molecular basis of acute myeloid leukemias: where are we now?","authors":"Alicja M Gruszka, Debora Valli, Myriam Alcalay","doi":"10.2217/ijh-2017-0002","DOIUrl":"https://doi.org/10.2217/ijh-2017-0002","url":null,"abstract":"<p><p>Although the treatment modalities for acute myeloid leukemia (AML) have not changed much over the past 40 years, distinct progress has been made in deciphering the basic biology underlying the pathogenesis of this group of hematological disorders. Studies show that AML development is a multicause, multistep and multipathway process. Accordingly, AMLs constitute a heterogeneous group of diseases. The thorough understanding of the molecular basis of AML is paving the way for better therapeutic approaches. Multiple novel drugs are being introduced and new, more efficient and less toxic formulations of conventional therapeutics are becoming available. Here, we review the recent advances in the comprehension of the molecular processes that lead to the onset of AML and its translation into clinical practice.</p>","PeriodicalId":14166,"journal":{"name":"International Journal of Hematologic Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2017-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.2217/ijh-2017-0002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"36568753","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}